| |
 |
 |
 |
 |
 |
 |
 |
 |
|
| HOME
> About Us > Alliances |
|
|
|
As a global leader in genetic medicine, we are involved in the promising
development areas, in line with our corporate philosophy: technologies
and patents from which the development of drugs originates. We have
formed the following strategic alliances to introduce several promising
development areas from universities:
| Daiichi Sankyo
Co., Ltd. |
 |
| Cooperating with us in development of HGF genetic medicine in the fields of peripheral arterial disease (PAD) and Ischemic heart disease (IHD) in Japan.
|
 For
details, see the news release. |
| Avontec GmbH |
|
| AnGes MG executed a cross licensing agreement, where AnGes received an exclusive license of STAT-1 decoy oligo for respiratory and dermal indications in Asia from Avontec and, Avontec received the exclusive right of NF-κB decoy oligo for psoriasis in Europe. |
| For
details, see the news release. |
| Vical, Inc. |
|
| AnGes MG and Vical executed a collaborative R&D agreement for Allovectin-7 which is for advanced metastatic melanoma as well as an equity investment agreement. In addition, AnGes MG obtained development and marketing rights of Allovectin-7 in Asia from Vical. |
| For
details, see the news release. |
| BioMarin Pharmaceutical Inc. |
|
| AnGes MG obtained exclusive rights to market and distribute Naglazyme for Mucopolysaccharidosis VI in Japan. |
| For
details, see the news release. |
| Transcription Factor Therapeutics, LLC |
|
| AnGes MG granted exclusive rights for development and marketing of NF-κB decoy oligo for the treatment of skin diseases (excluding psoriasis in Europe) and inflammatory bowel disease in North America and Europe to Transcription Factor Therapeutics. However, AnGes retained the rights for systemic delivery formulations of NF-κB decoy oligo for all these indications. |
| For
details, see the news release. |
|
GenomIdea Inc. (Consolidated subsidiary of AnGes MG) |
| Ishihara
Sangyo Kaisha, Ltd. |
|
| Cooperating with us in the manufacture and sale
of reagents with the use of HVJ envelope vectors. Ishihara Sangyo
Kaisha sells high-efficiency transfection kit GenomONE(R). |
| TSD Japan, Inc. |
|
| GenomIdea granted exclusive rights for manufacturing, development and marketing of GEN0101 (HVJ-E) for prostate cancer in Japan to TSD Japan. |
 |
|
 |
| |
The Group is accumulating
various know-how in the field of genetic medicine. If you are
a researcher, with original ideas and agree to the Group's policies,
we welcome your inquiries by all means. |
|
 |
|
 |
|
|
